Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, Inc. (NASDAQ: NTRA) has appointed Minetta Liu, M.D., as its new chief medical officer of oncology. Dr. Liu will lead the company's clinical and scientific efforts to establish the clinical utility of Signatera™ and integrate it into standard medical practice. Previously, she served at Mayo Clinic, contributing significantly to blood-based biomarker development. She succeeds Alexey Aleshin, now general manager for early cancer detection. This leadership change aims to enhance Natera's mission to improve cancer patient outcomes.
Natera, Inc. (NASDAQ: NTRA) announced that co-founder and Executive Chairman Matthew Rabinowitz, along with his family's trust, acquired 470,000 shares of the company, investing over $10 million in the last two months. This highlights Rabinowitz's confidence in Natera's mission and future initiatives in women's health, oncology, and transplant. Additionally, executive leaders and non-employee directors have opted for 100% equity compensation for 2022. Roelof Botha, lead independent director, also invested $5 million in Natera stock recently.
Natera, Inc. (NASDAQ: NTRA) reported first-quarter 2022 revenues of $194.1 million, a 27.5% increase from Q1 2021, driven primarily by strong product revenue growth of $190.0 million, reflecting a 57.8% year-over-year rise. The company processed approximately 489,300 tests, a 40.5% increase from the prior year. Following strong performance, Natera raised its 2022 revenue guidance from $770-790 million to $790-810 million. However, operating expenses rose 53.5% to $228.0 million, leading to a net loss of $138.6 million or ($1.45) per diluted share.
Natera, a leader in cell-free DNA testing, will release its Q1 2022 financial results on May 5, 2022, after market close. A conference call will follow at 1:30 PM PT to discuss these results and future outlook. The company's operations span oncology, women's health, and organ health, supported by over 100 peer-reviewed studies affirming their test accuracy. Natera is committed to integrating personalized genetic testing into standard care, thereby enhancing patient health.
Natera, Inc. (NASDAQ: NTRA) announced the RenaCARE study, aiming to assess the clinical utility of its Renasight genetic testing panel for chronic kidney disease (CKD). The study is projected to enroll 2,000 patients by Q2 2022, building on previous research showing that 89% of patients with positive multi-gene tests had actionable clinical implications. With 1,600 patients enrolled across 25 sites, the study will evaluate the impact of genetic findings on patient care management, satisfaction, and genetic literacy, contributing to evidence on the value of genetic testing in CKD.
Natera, Inc. (NASDAQ: NTRA) announced findings from a significant real-world study demonstrating a 21.1% positive yield for genetic findings using its Renasight™ test in chronic kidney disease (CKD) patients. Out of 1,007 patient samples analyzed, 220 positive results were identified across 48 genes, underscoring Renasight's effectiveness for genetic diagnoses in nephrology. The study highlights Renasight's potential to aid in clinical management and inform treatment options for the approximately 37 million U.S. adults affected by CKD.
Natera, Inc. (NASDAQ: NTRA) announced the publication of its DEDUCE study in the Journal of Heart and Lung Transplantation, demonstrating the effectiveness of its Prospera™ Heart test in assessing acute rejection in heart transplant patients. The study analyzed 703 prospective samples, achieving an impressive AUC of 0.86. The test shows potential to replace invasive biopsies and is backed by further trials, including NIH-supported studies anticipated to involve over 775 patients. This advancement highlights Natera's commitment to precision in heart transplant care.
Natera, Inc. (NASDAQ: NTRA) announced new findings regarding its Signatera personalized molecular residual disease test at the American Association for Cancer Research annual meeting held from April 8-13, 2022. The data focuses on triple negative breast cancer (TNBC) and high-risk hormone receptor-positive/HER2-negative patients. Key results include a significant correlation between detectable circulating tumor DNA (ctDNA) post-surgery and poor outcomes, with a lead time of up to 30 months before recurrence. This reinforces Signatera's role in enhancing patient management for breast cancer.
Natera, Inc. (NASDAQ: NTRA) announced the publication of the VALID study, validating its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test for assessing lung transplant rejection. The study analyzed 195 biopsy-matched samples, demonstrating the test's robust performance, with a 0.91 AUC for acute rejection against stable cases. Already in use at 25% of U.S. lung transplant centers, the Prospera test promises improved patient outcomes in lung transplantation. The study was published in Transplant Direct.
Natera, Inc. (NASDAQ: NTRA) announced the appointment of Sangeeta Bhorade, M.D., as the new vice president of organ health medical affairs.
Dr. Bhorade brings over 27 years of experience, including her role at the University of Chicago and Northwestern University. This addition follows other key hires, enhancing Natera's leadership in organ health. Her expertise is expected to drive innovation and improve patient care. With this new leadership, Natera aims to strengthen its position in the organ health sector.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
